Revolution Medicine reported striking Phase III outcomes for its once-daily oral KRAS-pathway candidate daraxonrasib (RASolute 302) in metastatic pancreatic ductal adenocarcinoma after prior treatment. Coverage highlights a median overall survival of 13.2 months versus 6.7 months with standard-of-care chemotherapy, with a reported hazard ratio of 0.40. The report also notes the market reaction, with Revolution shares jumping sharply after the data release. The emphasis is on whether daraxonrasib can convert early-generation KRAS disappointment into a more durable, clinically meaningful improvement for RAS-addicted pancreatic cancer. The company stated it is moving with urgency toward global regulatory submissions and plans to advance the therapy across a broader range of RAS-addicted cancers, including KRAS-driven lung and colorectal indications.